BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19069474)

  • 1. [Autoantibodies to steroid-producing ovarian cells in cancer patients].
    Bershteĭn LM; Poroshina TE; Vasil'ev DA; Orlova AV
    Vopr Onkol; 2008; 54(5):602-5. PubMed ID: 19069474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
    Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL
    Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-ovarian antibodies in sera of patients with ovarian tumors.
    Szubert S; Michalak S; Szpurek D; Moszynski R; Krygowska-Zielinska J; Sajdak S
    Immunol Lett; 2012 Dec; 148(2):133-7. PubMed ID: 23026238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive power of sexual hormones and tumor markers in endometrial cancer.
    Kanat-Pektas M; Yenicesu O; Gungor T; Bilge U
    Arch Gynecol Obstet; 2010 Apr; 281(4):709-15. PubMed ID: 19777250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibodies to thyroglobulin in patients with cancer].
    Bershteĭn LM; Golubev VN; L'vovich EG; Dil'man VM
    Vopr Onkol; 1977; 23(5):14-8. PubMed ID: 888413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer.
    Chen FC; Oskay-Ozcelik G; Bühling KJ; Köpstein U; Mentze M; Lichtenegger W; Sehouli J
    Anticancer Res; 2009 May; 29(5):1575-8. PubMed ID: 19443368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibronectin plasma levels in gynecological cancers.
    Grammatikakis IE; Botsis DC; Grigoriou OV; Dalamanga AN; Creatsas GC
    J BUON; 2010; 15(1):122-6. PubMed ID: 20414938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrioid adenocarcinoma with a functioning stroma.
    Hayasaka T; Nakahara K; Kojimahara T; Saito-Sekiguchi M; Motoyama T; Kurachi H
    J Obstet Gynaecol Res; 2007 Jun; 33(3):381-3. PubMed ID: 17578372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The cellular microenvironment of malignant tumors and its significance in their prognosis].
    Leenman EE; Mukhina MS
    Vopr Onkol; 2013; 59(4):444-52. PubMed ID: 24032217
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoimmune oophoritis in the adolescent.
    Welt CK
    Ann N Y Acad Sci; 2008; 1135():118-22. PubMed ID: 18574216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma calprotectin concentrations in women with endometrial carcinoma.
    Ni Bhriain H; Trovik J; Wik E; Stefansson IM; Akslen LA; Salvesen HB; Staff AC
    Gynecol Oncol; 2009 Sep; 114(3):491-5. PubMed ID: 19577278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of antiovarian antibodies (AOA) on ovarian responsiveness in vitro fertilization and embryo transfer.
    Zou SH; Zhang P; Song DP; Li B; Wu RY
    Neuro Endocrinol Lett; 2008 Dec; 29(6):949-52. PubMed ID: 19112403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regulation of ceruloplasmin activity in oncogynecological diseases].
    Gusarova IuN; Stepanova EV; Landesman EO; Koroleva OV; Vavilova TP; Makarov OV; Kosetskiĭ VN
    Vopr Med Khim; 2002; 48(4):388-93. PubMed ID: 12506616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemiluminescent optical fiber immunosensor for detection of autoantibodies to ovarian and breast cancer-associated antigens.
    Salama O; Herrmann S; Tziknovsky A; Piura B; Meirovich M; Trakht I; Reed B; Lobel LI; Marks RS
    Biosens Bioelectron; 2007 Feb; 22(7):1508-16. PubMed ID: 16904309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estradiol-2-hydroxylase activity in tumors of the corpus uteri and breast: the effect of smoking].
    Tsyrlina EV; Manikhas (Kolesnik) OS; Vasil'ev DA; Kovalenko IG; Bershteĭn LM
    Vopr Onkol; 2000; 46(3):306-10. PubMed ID: 10976277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-specific changes in the complement system in neoplastic processes].
    Tiagotin IuV; Rybakova LP; Golota GZ; Ishchenko AM
    Vopr Onkol; 2002; 48(2):206-10. PubMed ID: 12227070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of unexplained infertility with gonadotropin and ovarian antibodies.
    Shatavi SV; Llanes B; Luborsky JL
    Am J Reprod Immunol; 2006; 56(5-6):286-91. PubMed ID: 17076672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
    Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
    Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis.
    Tamesa MS; Kuramitsu Y; Fujimoto M; Maeda N; Nagashima Y; Tanaka T; Yamamoto S; Oka M; Nakamura K
    Electrophoresis; 2009 Jun; 30(12):2168-81. PubMed ID: 19582718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.